Sugawara Tamie, Ohkusa Yasushi, Taniguchi Kiyosu, Miyazaki Chiaki, Momoi Mariko, Okabe Nobuhiko
Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan.
Infectious Disease Surveillance Center, National Institute of Infectious Diseases, Japan.
J Infect Chemother. 2019 Jun;25(6):423-426. doi: 10.1016/j.jiac.2019.01.008. Epub 2019 Feb 7.
Even though abnormal behavior related with influenza and neuraminidase inhibitors (NI) has been discussed, the risks of acetaminophen and co-administration of NI and acetaminophen have not been examined. This study assesses those risks.
All cases of patients with influenza who present with severe abnormal behavior are reported by physicians of all clinics and hospitals throughout Japan. The numbers of people diagnosed as having influenza, whether prescribed NI and acetaminophen or not, were extracted from the National Database of Electronic Medical Claims (NDBEMC). The study period was from September 2009 to March 2016.
We found two consistent results among four combinations of age class and severity. The one was that patients who did not use NI or acetaminophen showed significantly higher incidence of abnormal behavior than zanamivir with acetaminophen, another one was that patients with oseltamivir only has higher incidence than zanamivir with acetaminophen. Concerning about acetaminophen, the use of it significantly decrease risk for severe and the most severe instances in 5-9-year-old patients with laninamivir and the severe instances in 10-19-year-old patients with zanamivir.
We also demonstrated that acetaminophen alone or co-administered with NI does not seem to raise the risk of abnormal behavior in influenza patients.
尽管已经讨论了与流感和神经氨酸酶抑制剂(NI)相关的异常行为,但对乙酰氨基酚以及NI与乙酰氨基酚联合使用的风险尚未进行研究。本研究评估这些风险。
日本各地所有诊所和医院的医生报告所有出现严重异常行为的流感患者病例。从国家电子医疗索赔数据库(NDBEMC)中提取被诊断患有流感的人数,无论是否开具了NI和乙酰氨基酚。研究期间为2009年9月至2016年3月。
我们在年龄组和严重程度的四种组合中发现了两个一致的结果。一个是未使用NI或乙酰氨基酚的患者出现异常行为的发生率显著高于扎那米韦与乙酰氨基酚联合使用的患者,另一个是仅使用奥司他韦的患者发生率高于扎那米韦与乙酰氨基酚联合使用的患者。关于乙酰氨基酚,在使用拉尼米韦的5至9岁患者中,使用它可显著降低严重和最严重病例的风险,在使用扎那米韦的10至19岁患者中,可降低严重病例的风险。
我们还证明,单独使用乙酰氨基酚或与NI联合使用似乎不会增加流感患者出现异常行为的风险。